Succinyl hydroxamates as potent and selective non-peptidic inhibitors of procollagen C-proteinase: Design, synthesis, and evaluation as topically applied, dermal anti-scarring agents

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 24, 2008, Pages 6562-6567

  Bailey, Simon ^a   Fish, Paul V ^a   Billotte, Stephane ^a   Bordner, Jon ^b   Greiling, Doris ^a   James, Kim ^a   McElroy, Andrew ^a   Mills, James E ^a   Reed, Charlotte ^a   Webster, Robert ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b PFIZER INC   (United States)

Author keywords

Anti scarring; Conformational analysis; Procollagen C proteinase; Succinyl hydroxamates; Transepidermal delivery

Indexed keywords

ANTIFIBROTIC AGENT; COLLAGEN; HYDROXAMIC ACID DERIVATIVE; MATRIX METALLOPROTEINASE; PROCOLLAGEN C PROTEINASE; PROCOLLAGEN C PROTEINASE INHIBITOR; UK 383367; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DOG; DRUG DESIGN; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; NONHUMAN; RAT; SCAR FORMATION; WOUND HEALING;

ADMINISTRATION, CUTANEOUS; BONE MORPHOGENETIC PROTEIN 1; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; CICATRIX; CICATRIX, HYPERTROPHIC; DRUG DESIGN; EPIDERMIS; FIBROSIS; HUMANS; HYDROXAMIC ACIDS; INHIBITORY CONCENTRATION 50; MODELS, CHEMICAL; MOLECULAR CONFORMATION; OXAZOLES;

EID: 56249097861     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.10.036     Document Type: Article

References (30)

1. Trojanowska M., LeRoy E.C., Eckes B., and Krieg T. J. Mol. Med. 76 (1998) 266
2. Border W.A., and Noble N.A. NEJM 331 (1994) 1286
3. Lee S., Solow-Corero D.E., Kessler E., Takahara K., and Greenspan D.S. J. Biol. Chem. 272 (1997) 19059
4. Kessler E. Procollagen C-Proteinase. The Handbook of Proteolytic Enzymes (1998), Academic press pp 1-5
5. Kessler E., Takahara T., Biniamov L., Brusel M., and Greenspan D.S. Science 271 (1996) 360
6. Rhett J.M., Ghatnekar G.S., Palatinus J.A., O'Quinn M., Yost M.J., and Gourdie R.G. Trends Biotechnol. 26 (2008) 173
7. For a review of PCP inhibitors, see:. Turtle E.D., and Ho W.-B. Expert Opin. Ther. Patents 14 (2004) 1185
8. Bailey, S.; Billotte, S.; Derrick, A. M.; Fish, P. V.; James, K.; Thomson, N. M. WO 2001047901.
9. Bailey, S.; Fish, P. V.; James, K.; McElroy, A. Abstracts of Papers, 227th ACS Nation Meeting, Anaheim, CA, March 28-April 1, 2004.
10. Fish P.V., Allan G.A., Bailey S., Blagg J., Butt R., Collis M.G., Greiling D., James K., Kendall J., McElroy A., McCleverty D., Reed C., Webster R., and Whitlock G.A. J. Med. Chem. 50 (2007) 3442
11. Derrick, A. M.; Thomson, N. M. EP 1199301, 2002.
12. Wipf P., and Miller C.P. Tetrahedron Lett. 33 (1992) 907
13. Barrish J.C., Singh J., Spergel S.H., Han W.C., Kissick T.P., Kronenthal D.R., and Mueller R.H. J. Org. Chem. 58 (1993) 4494
14. Wipf P., and Miller C.P. J. Org. Chem. 58 (1993) 3604
15. Complete experimental procedures for all assays can be found in Ref. 9.
16. Kasting G.B., Smith R.L., and Cooper E.R. Pharmacol. Skin Vol. 1 (1987), Karger, Basel p 138
17. Hadgraft J., and Valenta C. Int. J. Pharm. 200 (2000) 243
18. Potts R.O., and Guy R.H. Pharm. Res. 12 (1995) 1628
19. Lijnen H.R., and Collen D. Plasminogen (2003) 189
20. Clark R.A.F., McCoy G.A., Folkvord J.M., and McPherson J.M. J. Cell. Physiol. 170 (1997) 69
21. Newstead E.L., Gaboardi S., Huggins J.P., and Greiling D. J. Dermatol. Sci. 16 Suppl. 1 (1998) S128
22. Barry B.W. Dermatological Formulations in Drugs and the Pharmaceutical Sciences (1983), Marcel Dekker Inc., NY p 127
23. Roberts M.S. Structure-permeability considerations in percutaneous absorption. In: Scott R.C., Guy R.H., Hadgraft J., and Bodde H.E. (Eds). Prediction, of Percutaneous Penetration-Methods, Measurements, and Modelling Vol. 2 (1991), IBC Technical Services 210
24. 2O have been deposited with the Cambridge Crystallographic Data Centre as Supplementary Publication Number CCDC707773. Copies of the data can be obtained free of charge, on application to CCDC, 12 Union Road, Cambridge, CB2 1EZ, UK.
25. An analysis of crystal structures of related compounds available in the PDB and CCDC also showed planar arrangements between the carboxamide and the oxadiazole and oxazole rings.
26. 2/h.
27. Grady, M. W.; Bloor, S. 1999, EP 930069.
28. Duncan M.R., Frazier K.S., Abramson S., Williams S., Klapper H., Huang X., and Grotendorst G.R. FASEB J. 13 (1999) 1774
29. Allan G.A., Gedge J.I., Nedderman A.N.R., Roffey S.J., Small H.F., and Webster R. Xenobiotica 36 (2006) 399
30. Reid R.R., Mogford J.E., Butt R., deGiorgio-Miller A., and Mustoe T.A. Wound Rep. Reg. 14 (2006) 138